



Endologix  
Investor Relations Department  
2 Musick  
Irvine, CA 92618  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: ELGX

Last Trade:	4.26
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	0.00 (0.000%)
Day Range	4.16 - 4.31
52-Week Range	4.08 - 13.30
Volume	715,241

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- **Addressing a signi... [\(more\)](#)**

## Stock Performance



### Press Releases [\[ View all \]](#)

- Aug 17, 2017*  
[Endologix Announces Positive Clinical Results from the LEOPARD Clinical Study](#)
- Aug 2, 2017*  
[Endologix Reports Second Quarter 2017 Financial Results](#)
- Jul 12, 2017*  
[Endologix, Inc. to Announce Second Quarter 2017 Financial Results on August 2, 2017](#)
- Jul 10, 2017*  
[Endologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference](#)
- Jun 3, 2017*  
[Endologix Presents Positive Two-Year Clinical Data from the Nellix® EVAS FORWARD IDE Trial](#)

### Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 1, 2017*  
[Annual Report \(10-K\)](#)
- May 1, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*  
[Quarterly Report \(10-Q\)](#)